We also provided the first evidence demonstrating that the long-term oral administration of TGPE could successfully delay the development and progression of T2DM by reducing ROS and inflammation, balancing lipid metabolism in the liver, and increasing serum levels of adiponectin and leptin in STZ/HFD-induced T2DM rats. This evidence concerns the gene LEP and type 2 diabetes mellitus.